Rheumatoid Arthritis: Foltz V

 Topic:  
Hints · Remembered Topics    
  Start Here  Overview  World Articles  Find Experts  Books & DVDs  Help 
 
Column View Map 4 Articles   Help
A digest of articles written 1999 and later, on the topic "Arthritis, Rheumatoid," originating from Planet Earth —» Foltz V.  Display:  All Citations ·  All Abstracts
1 Article The gap between practice and guidelines in the choice of first-line disease modifying antirheumatic drug in early rheumatoid arthritis: results from the ESPOIR cohort. 2009

Benhamou M, Rincheval N, Roy C, Foltz V, Rozenberg S, Sibilia J, Schaeverbeke T, Bourgeois P, Ravaud P, Fautrel B. · Department of Rheumatology, University of Paris VI, Pitie Salpetriere Hospital, Paris, France. · J Rheumatol. · Pubmed #19286850 No free full text.

Abstract: OBJECTIVE: To compare rheumatologists' prescription for first disease modifying antirheumatic drug (DMARD) in early rheumatoid arthritis (RA) in real-life settings with 2 clinical practice guidelines (CPG), the French Society of Rheumatology/STPR 2004 and EULAR/ESCISIT 2007, and thus assess the gap between practices and guidelines. Method. ESPOIR was a French multicenter cohort study of 813 patients with early arthritis between 2002 and 2005. "Definite" and "probable" RA were defined according to ACR criteria and the level of diagnostic certainty. The objectives were to assess conformity between the observed first-line DMARD prescribed for those patients and the DMARD recommended in the guidelines; and to conduct a mail survey of patients' usual rheumatologists to investigate the reasons for their nonconformity with guidelines. RESULTS: In total 627 patients with definite or probable RA were identified. Conformity rates were 58% for STPR guidelines and 54% for EULAR guidelines. At 6 months, 83 (34%) patients with early RA did not receive any DMARD. Main determinants associated with conformity to guidelines were disease activity and presence of severity-predictive factors. The main reason leading to a discrepancy between guidelines and daily practice appeared to be diagnostic uncertainty, i.e., the difficulty to reliably assess RA diagnosis as early as the first visits to the rheumatologist. CONCLUSION: There is a substantial gap between CPG and rheumatologists' daily practice concerning the first DMARD to prescribe in early RA. This is explained mainly by diagnostic uncertainty. More attention should be paid in future guidelines to the diagnostic difficulties of early RA.

2 Minor Ultrasound and magnetic resonance imaging did not provide early assessment of biotherapy response in patients with rheumatoid arthritis. 2009

Foltz V, Loeuille D, Etchepare F, Chary-Valckenaere I, Rosenberg C, Tanguy ML, Fautrel B, Bourgeois P. · No affiliation provided · Joint Bone Spine. · Pubmed #18945634 No free full text.

This publication has no abstract.

3 Minor Ultrasound ability in early diagnosis of stress fracture of metatarsal bone. free! 2006

Banal F, Etchepare F, Rouhier B, Rosenberg C, Foltz V, Rozenberg S, Koeger AC, Fautrel B, Bourgeois P. · No affiliation provided · Ann Rheum Dis. · Pubmed #16769791 links to  free full text

This publication has no abstract.

4 Minor Regression of subacute cutaneous lupus erythematosus in a patient with rheumatoid arthritis treated with a biologic tumor necrosis factor alpha-blocking agent: comment on the article by Pisetsky and the letter from Aringer et al. free! 2002

Fautrel B, Foltz V, Frances C, Bourgeois P, Rozenberg S. · No affiliation provided · Arthritis Rheum. · Pubmed #12115253 links to  free full text

This publication has no abstract.